<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099500</url>
  </required_header>
  <id_info>
    <org_study_id>ADI-US-CLIN-001</org_study_id>
    <nct_id>NCT02099500</nct_id>
  </id_info>
  <brief_title>Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia</brief_title>
  <official_title>An Open-label, Non-Randomized, Patient Funded, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Via Intramuscular Injections for the Treatment of Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ageless Regenerative Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ageless Regenerative Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, multi center, patient sponsored study of&#xD;
      Adipose-Derived Stromal Cell (ASC) implantation via intramuscular injections in patients who&#xD;
      have critical limb ischemia not amenable for revascularization.&#xD;
&#xD;
      The intent of this clinical study is to answer the questions: 1) Is the proposed treatment&#xD;
      safe and 2) Is treatment effective in improving the disease pathology of patients with&#xD;
      diagnosed critical limb ischemia ASCs will be collected from the patient's adipose-derived&#xD;
      tissue (body fat). Using local anesthesia, Liposuction will be performed to collect the&#xD;
      adipose tissue specimen. The adipose tissue is then transferred to the laboratory for&#xD;
      separation of the adipose tissue derived stem cells. In addition, peripheral blood will be&#xD;
      collected for isolation of platelet rich plasma, which are then combined with the ASC's for&#xD;
      intramuscular injection into the lower limb.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no participants enrolled&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement from baseline in perfusion as measured by ankle-brachial index and collateral artery number</measure>
    <time_frame>6 months</time_frame>
    <description>Contrast Angiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events reported</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in improvement or resolution of ulcer or gangrene</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>Visual assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb Salvage</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Assessed with doppler to measure blood flow to the affected area.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in Quality of Life</measure>
    <time_frame>3 months, 6 months</time_frame>
    <description>King's College Hospital's Vascular Quality of Life Questionnaire</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Stem Cell Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liposuction</intervention_name>
    <description>Liposuction using aspiration syringe and tumescent local anesthesia</description>
    <arm_group_label>Stem Cell Injection</arm_group_label>
    <other_name>Adipose-Derived Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stem Cell Injection</intervention_name>
    <description>Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest</description>
    <arm_group_label>Stem Cell Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ~ 18 years&#xD;
&#xD;
          -  Existence of limb ischemia, with clinical presentation corresponding to Rutherford&#xD;
             Categories 2-6 as defined in the reporting standards adopted by \ the Society of&#xD;
             Vascular Surgeons, or corresponding to the Leriche-Fontaine Classification, stages II,&#xD;
             III, or IV&#xD;
&#xD;
          -  Patients with, ischemia and ischemic ulceration provided patient have angiographic&#xD;
             evidence of vascular compromise and is not a candidate for revascularization&#xD;
&#xD;
          -  Stable and on optimal medical management for &gt; 60 days as follows:&#xD;
&#xD;
          -  Clopidogrel/aspirin therapy or other anticoagulation therapy, cholesterol- lowering&#xD;
             agent, and⁄or antihypertensive medication&#xD;
&#xD;
          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤14,000, Platelet count ≥ 50,000&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL, and INR ≤ 1.6 (unless taking warfarin) or PTT &lt; 1.5× control&#xD;
             (to avoid bleeding complications). INR values for patients taking warfarin will be&#xD;
             corrected prior to the procedure&#xD;
&#xD;
          -  Patient meets at least one of the following diagnostic criteria for the index limb:&#xD;
&#xD;
               1. ABI&lt;.5mmHg&#xD;
&#xD;
               2. TcpO2 &lt;20 mm Hg when lying down and breathing room air, if available&#xD;
&#xD;
               3. Or, nonhealing ulcer due to local arterial compromise with no opportunity for&#xD;
                  revascularization&#xD;
&#xD;
          -  At least one non-healing distal extremity ischemic ulcer as confirmed by a vascular&#xD;
             surgeon&#xD;
&#xD;
          -  Up to date on all age and gender appropriate cancer screening per American Cancer&#xD;
             Society&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female who is pregnant or nursing, or is of childbearing potential and not using a&#xD;
             reliable method of contraception&#xD;
&#xD;
          -  Any medical problems contraindicating tumescent syringe liposuction&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Patient determined to be nonsurgical candidate due to reasons such as&#xD;
&#xD;
               1. High-risk medical conditions&#xD;
&#xD;
               2. Unstable cardiac disease&#xD;
&#xD;
               3. Stroke or transient ischemic attack leading to limitations in lower extremities&#xD;
                  or occurring within 180 days prior to the initial screening visit&#xD;
&#xD;
               4. Severe arthritis or other musculoskeletal disorder.&#xD;
&#xD;
          -  Systolic blood pressure (supine) ≤ 90 mmHg&#xD;
&#xD;
          -  Resting heart rate &gt; 100 bpm&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (HgbA1c &gt; 10%)&#xD;
&#xD;
          -  Life-threatening complications of limb ischemia necessitating immediate amputation&#xD;
&#xD;
          -  Uncorrected iliac artery occlusion on index side unless corrected with stent&#xD;
&#xD;
          -  Extensive necrosis of the index limb or other conditions that make amputation&#xD;
             inevitable (Rutherford Category 6)&#xD;
&#xD;
          -  Active clinical infection within one week of enrollment&#xD;
&#xD;
          -  Treatment with immunosuppressant drugs&#xD;
&#xD;
          -  Known drug or alcohol dependence, or any other factors which will interfere with the&#xD;
             study conduct or interpretation of the results&#xD;
&#xD;
          -  Not suitable to participate in the opinion of the principal investigator&#xD;
&#xD;
          -  History cancer (other than non-melanoma skin cancer or in situ cervical cancer) within&#xD;
             five years preceding study entry&#xD;
&#xD;
          -  Unwilling and/or not able to give written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon McQuillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ageless Regenerative Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ageless Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Lower Limb Ulcer</keyword>
  <keyword>Gangrene</keyword>
  <keyword>Amputation</keyword>
  <keyword>Lower Limb Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

